Resources for Human Health from the Plant Kingdom: The Potential Role of the Flavonoid Apigenin in Cancer Counteraction.

apigenin bioavailability combined modality therapies flavonoids neoplasms

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Dec 2023
Historique:
received: 28 11 2023
revised: 20 12 2023
accepted: 21 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

Apigenin is one of the most widespread flavonoids in the plant kingdom. For centuries, apigenin-containing plant preparations have been used in traditional medicines to treat diseases that have an inflammatory and/or degenerative component. In the 1980s, apigenin was proposed to interfere with the process of carcinogenesis. Since then, more and more evidence has demonstrated its anticancer efficacy, both in vitro and in vivo. Apigenin has been shown to target signaling pathways involved in the development and progression of cancer, such as PI3K/Akt/mTOR, MAPK/ERK, JAK/STAT, NF-κB, and Wnt/β-catenin pathways, and to modulate different hallmarks of cancer, such as cell proliferation, metastasis, apoptosis, invasion, and cell migration. Furthermore, apigenin modulates PD1/PD-L1 expression in cancer/T killer cells and regulates the percentage of T killer and T regulatory cells. Recently, apigenin has been studied for its synergic and additive effects when combined with chemotherapy, minimizing the side effects. Unfortunately, its low bioavailability and high permeability limit its therapeutic applications. Based on micro- and nanoformulations that enhance the physical stability and drug-loading capacity of apigenin and increase the bioavailability of apigenin, novel drug-delivery systems have been investigated to improve its solubility.

Identifiants

pubmed: 38203418
pii: ijms25010251
doi: 10.3390/ijms25010251
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Association for Research on Integrative Oncology Therapies (ARTOI) Foundation
ID : N. A.

Auteurs

Laura Fossatelli (L)

Association for Research on Integrative Oncology Therapies (ARTOI) Foundation, Via Ludovico Micara 73, 00165 Rome, Italy.

Zaira Maroccia (Z)

Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.

Carla Fiorentini (C)

Association for Research on Integrative Oncology Therapies (ARTOI) Foundation, Via Ludovico Micara 73, 00165 Rome, Italy.

Massimo Bonucci (M)

Association for Research on Integrative Oncology Therapies (ARTOI) Foundation, Via Ludovico Micara 73, 00165 Rome, Italy.

Classifications MeSH